Authors

Carlos L. Arteaga, MD

Latest:

Dr. Arteaga Discusses the CALGB 40603 Trial

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Carlos L. Arteaga, MD, Vanderbilt

Carlos L. Arteaga, MD, Vanderbilt University

Carlos R. Bachier, MD

Latest:

Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Carlton Brown, RN, PhD

Latest:

Carlton Brown Describes the ONS Social Media Efforts

Oncology Nursing Society President Carlton Brown Describes the ONS Social Media Efforts

Carlton Brown, RN, PhD, AOCN

Latest:

ONS President Carl Brown on Key Messages of the Congress

Carlton Brown Describes Key Messages of the ONS Congress

Carmelina E. Heydrich, MS, Katherine A. Schneider, MPH

Latest:

When to Consider Referral to a Genetic Counselor for Lesser Known Cancer Syndromes

Experts discuss the clinical features, gene function, and medical management recommendations for six hereditary cancer syndromes.

Carmelo Nucera, MD, PhD

Latest:

Dr. Nucera Discusses the Role of RNA in Thyroid Cancer

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Carol Aghajanian, MD

Latest:

Dr. Aghajanian on Ovarian Cancer Trial Endpoints

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Carol Bush, BS, RN

Latest:

Carol Bush on Navigators and Healthcare Reform

Carol Bush, BS, RN, Patient Navigator, Midwest Cancer Alliance, The University of Kansas Cancer Center, discusses the role of oncology nurse navigators in healthcare reform.

Carol G. Kelley, PhD, RN

Latest:

The Benefits for Nurses of Using Psychosocial Cancer Registry Data

Registries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.

Carol J. Bush, BS, RN

Latest:

Carol Bush on the MCA Telehealth Network

Carol Bush, BS, RN, from the The University of Kansas Cancer Center, on the Midwest Cancer Alliance Telehealth Network

Carol Tringali, MS, RN

Latest:

Carol Tringali on Closing the Gaps in Psychosocial Care

Carolina Moreno Atanasio, MD

Latest:

Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naÃ¯ve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Caroline Robert, MD, PhD

Caroline Robert, MD, PhD, is the head of the Dermatology Unit at Gustave Roussy.

Latest:

Dr Robert on the Role of Adjuvant Anti–PD-1 Therapy in Resected Stage IIB/C Melanoma

Caroline Robert, MD, PhD, discusses the role of adjuvant anti–PD-1 therapy in resected stage IIB/IIC melanoma based on findings from the KEYNOTE-716 and CheckMate 76K trials.

Caroline Seymour

Managing Editor,

Latest:

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

Carolyn D. Britten, MD

Latest:

Dr. Carolyn Britten on Next Steps in Immunotherapy

Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.

Carolyn Lefkowits, MD

Latest:

Dr. Lefkowits Addresses Misconceptions About Palliative Care Integration

Carolyn Lefkowits, MD, gynecologic oncologist, and palliative care doctor, at the University of Colorado, addresses common misconceptions regarding palliative care integration.

Carolyn Owen, MD, University of Calgary

Caron Jacobson, MD

Latest:

The Future of CAR T-Cell Therapy in LBCL

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, look at both the regulatory and clinical components that will shape future research and utilization of CAR T-cell therapy in oncology and beyond.